机构

• 上海药物研究所 [42]
• 金属研究所 [7]
• 过程工程研究所 [5]
• 化学研究所 [1]
• 昆明植物研究所 [1]
• 上海应用物理研究所 [1]
• 更多

采集方式

• OAI收割 [60]
• iSwitch采集 [2]

内容类型

• 期刊论文 [62]

发表日期

• 2024 [2]
• 2021 [2]
• 2020 [4]
• 2019 [4]
• 2018 [4]
• 2017 [5]
• 更多

学科主题

• Microbiolo... [2]
• Biotechnol... [1]
• Chemistry [1]
• Mycology [1]
• Pharmacolo... [1]
• Respirator... [1]
• 更多

筛选

浏览/检索结果: 共62条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择题名升序题名降序提交时间升序提交时间降序作者升序作者降序发表日期升序发表日期降序 Integrative study of lung cancer adeno-to-squamous transition in EGFR TKI resistance identifies RAPGEF3 as a therapeutic target 期刊论文  OAI收割 NATIONAL SCIENCE REVIEW, 2024, 卷号: 11, 期号: 12, 页码: 20 作者:  Wang, Hua;  Tang, Shijie;  Wu, Qibiao;  He, Yayi;  Zhu, Weikang   |  收藏  |  浏览/下载：14/0  |  提交时间：2025/02/28 EGFR-mutant lung cancer  adeno-to-squamous transition  tyrosine kinase inhibitor resistance  transcription factor network  RAPGEF3   Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitor 期刊论文  OAI收割 BIOORGANIC CHEMISTRY, 2024, 卷号: 143, 页码: 16 作者:  Sun, Yaoliang;  Chen, Zhiwen;  Liu, Guobin;  Chen, Xiaoai;  Shi, Zihan   |  收藏  |  浏览/下载：28/0  |  提交时间：2024/03/25 Inhibitor  Cancer  Threonine tyrosine kinase (TTK)  Covalent   Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells 期刊论文  OAI收割 THORACIC CANCER, 2021, 页码: 9 作者:  Zhang, Mi;  Quan, Haitian;  Fu, Li;  Li, Yun;  Fu, Haoyu   |  收藏  |  浏览/下载：65/0  |  提交时间：2021/05/24 EGFR‐  mutant non‐  small cell lung cancer  famitinib  HS‐  10296  multi‐  targeted tyrosine kinase inhibitor  third‐  generation EGFR inhibitor   Musarin, a novel protein with tyrosine kinase inhibitory activity from Trametes versicolor, accepted inhibits colorectal cancer stem cell growth 期刊论文  OAI收割 BIOMEDICINE & PHARMACOTHERAPY, 2021, 卷号: 144, 页码: 112339 作者:  He,YingYing;  Liu,Shubai;  Newburg,David S.   |  收藏  |  浏览/下载：49/0  |  提交时间：2022/04/02 Trametes versicolor  Cancer stem cell  Tyrosine kinase inhibitor  EGFR  Colorectal cancer  FACTOR RECEPTOR  POLYSACCHAROPEPTIDE  RESISTANCE  TARGET  EGFR  TOOL  PSP  DNA   DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2020, 页码: 9 作者:  Dai, Meng-di;  Wang, Yue-liang;  Fan, Jun;  Dai, Yang;  Ji, Yin-chun   |  收藏  |  浏览/下载：86/0  |  提交时间：2021/05/24 receptor tyrosine kinase  FGFR inhibitor  DW14383  antitumor activity   Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report 期刊论文  OAI收割 FRONTIERS IN ONCOLOGY, 2020, 卷号: 10 作者:  Yang, Zi-yan;  Huang, Jia-huan;  Chen, Bo;  Xu, Chun-wei;  Lei, Lei   |  收藏  |  浏览/下载：56/0  |  提交时间：2020/11/30 salivary duct carcinoma  tyrosine kinase inhibitor  pyrotinib  HER2 positive  targeted   Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2020, 卷号: 41, 期号: 3, 页码: 415-422 作者:  Lai, Meng-zhen;  Song, Pei-ran;  Dou, Dou;  Diao, Yan-yan;  Tong, Lin-jiang   |  收藏  |  浏览/下载：20/0  |  提交时间：2020/07/01 B cell receptor  Bruton's tyrosine kinase  ibrutinib  small-molecule inhibitor  B cell malignancies   CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study 期刊论文  OAI收割 FRONTIERS IN ONCOLOGY, 2020, 卷号: 10, 页码: 9 作者:  Li, Hailin;  Zhang, Rui;  Wang, Siwen;  Fang, Mengjie;  Zhu, Yongbei   |  收藏  |  浏览/下载：63/0  |  提交时间：2020/04/07 computed tomography  radiomics  non-small-cell lung cancer  tyrosine kinase inhibitor resistance  anaplastic lymphoma kinase   3-Deoxy-2 beta,16-dihydroxynagilactone E, a natural compound from Podocarpus nagi, preferentially inhibits JAK2/STAT3 signaling by allosterically interacting with the regulatory domain of JAK2 and induces apoptosis of cancer cells 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2019, 卷号: 40, 期号: 12, 页码: 1578-1586 作者:  Shan, Hui;  Yao, Sheng;  Ye, Yang;  Yu, Qiang   |  收藏  |  浏览/下载：17/0  |  提交时间：2020/07/01 JAK/STAT  3-deoxy-2 beta,16-dihydroxynagilactone E  tyrosine kinase inhibitor  allosteric inhibitor  cancer   Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure-activity relationship, crystal structural characterization and and in vivo study 期刊论文  OAI收割 ACTA PHARMACEUTICA SINICA B, 2019, 卷号: 9, 期号: 2, 页码: 351-368 作者:  Wei, Peng;  Liu, Bo;  Wang, Ruifeng;  Gao, Yinglei;  Li, Lanlan   |  收藏  |  浏览/下载：51/0  |  提交时间：2020/07/01 Fibroblast growth factor  Tyrosine kinase receptor  Structure-based  Crystallography  Selectivity  Hybrid  5-Hydrosulfonyl-5H- pyrrolo[2.3-b]pyrazine  Inhibitor